View Financial HealthSynthaverse 배당 및 자사주 매입배당 기준 점검 0/6Synthaverse 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-10.3%자사주 매입 수익률총 주주 수익률-10.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 04Synthaverse S.A., Annual General Meeting, Jun 29, 2026Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time.공시 • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.공시 • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.26, the stock trades at a trailing P/E ratio of 74.3x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 48% over the past three years.Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (85% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (6.6% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (€67.6m market cap, or US$72.9m).공시 • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024Reported Earnings • Nov 25Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses.New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (64% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.9m).공시 • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €1.22, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total returns to shareholders of 68% over the past year.공시 • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.17, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 7.5% over the past year.공시 • Dec 02BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million.BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: PLN 5.3Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.Reported Earnings • Sep 10Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 73% share price gain to €1.17, the stock trades at a trailing P/E ratio of 73.9x. Average trailing P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 40% over the past year.공시 • Jun 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022, at 11:00 Central European Standard Time.Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021).Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020).공시 • Feb 02+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2022 Results on Nov 09, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2022 results on Nov 09, 2022Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €1.10, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 58% over the past year.Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020).Reported Earnings • Sep 06Second quarter 2021 earnings released: EPS zł0.047 (vs zł0.007 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł14.5m (up 56% from 2Q 2020). Net income: zł2.96m (up zł3.38m from 2Q 2020). Profit margin: 20% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.공시 • May 05BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment ArmBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm.공시 • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2021 Results on Nov 09, 2021BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2021 results on Nov 09, 2021Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 6NQ 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 6NQ 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Synthaverse 배당 수익률 vs 시장6NQ의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (6NQ)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Biotechs)2.4%분석가 예측 (6NQ) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 6NQ 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 6NQ 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 6NQ 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 6NQ 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 16:22종가2026/06/09 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Synthaverse S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 04Synthaverse S.A., Annual General Meeting, Jun 29, 2026Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time.
공시 • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025
Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
공시 • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.26, the stock trades at a trailing P/E ratio of 74.3x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 48% over the past three years.
Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (85% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (6.6% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (€67.6m market cap, or US$72.9m).
공시 • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024
Reported Earnings • Nov 25Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses.
New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (64% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.9m).
공시 • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.
Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €1.22, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total returns to shareholders of 68% over the past year.
공시 • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.17, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 7.5% over the past year.
공시 • Dec 02BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million.BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: PLN 5.3
Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.
Reported Earnings • Sep 10Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).
Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 73% share price gain to €1.17, the stock trades at a trailing P/E ratio of 73.9x. Average trailing P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 40% over the past year.
공시 • Jun 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022, at 11:00 Central European Standard Time.
Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021).
Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020).
공시 • Feb 02+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2022 Results on Nov 09, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2022 results on Nov 09, 2022
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €1.10, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 58% over the past year.
Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020).
Reported Earnings • Sep 06Second quarter 2021 earnings released: EPS zł0.047 (vs zł0.007 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł14.5m (up 56% from 2Q 2020). Net income: zł2.96m (up zł3.38m from 2Q 2020). Profit margin: 20% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.
공시 • May 05BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment ArmBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm.
공시 • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2021 Results on Nov 09, 2021BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2021 results on Nov 09, 2021
Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses.